142 related articles for article (PubMed ID: 33234924)
1. Rapidly Evolving Diffuse Omental Carcinomatosis of Prostate Cancer in 68Ga-PSMA PET/CT.
Hoberück S; Sommer U; Grey A; Hölscher T; Baretton GB; Kotzerke J
Clin Nucl Med; 2021 Apr; 46(4):e216-e217. PubMed ID: 33234924
[TBL] [Abstract][Full Text] [Related]
2. Peritoneal Carcinomatosis From Metastatic Prostate Cancer Identified on 68 Ga-Prostate-Specific Membrane Antigen PET/CT.
Lau KS; Le K; Bui C; Wong VCK; Mansberg R
Clin Nucl Med; 2023 Aug; 48(8):704-706. PubMed ID: 37290423
[TBL] [Abstract][Full Text] [Related]
3. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
4. Total-Body
Pomykala KL; Czernin J; Grogan TR; Armstrong WR; Williams J; Calais J
J Nucl Med; 2020 Mar; 61(3):405-411. PubMed ID: 31541035
[TBL] [Abstract][Full Text] [Related]
5. 68Ga-PSMA Uptake in Brain Metastasis of Gastric Carcinoma.
Kesim S; Oksuzoglu K
Clin Nucl Med; 2022 Sep; 47(9):e585-e586. PubMed ID: 35930713
[TBL] [Abstract][Full Text] [Related]
6. Solitary Femoral Nodal Metastasis Identified With 68Ga-Prostate-Specific Membrane Antigen PET/CT.
Hilliar L; Yip JWL; Wong VCK; Le K; Mansberg R
Clin Nucl Med; 2021 Feb; 46(2):173-174. PubMed ID: 33315675
[TBL] [Abstract][Full Text] [Related]
7. Prospective evaluation of the performance of [
Abufaraj M; Grubmüller B; Zeitlinger M; Kramer G; Seitz C; Haitel A; Baltzer P; Hacker M; Wadsak W; Pfaff S; Wiatr T; Mitterhauser M; Shariat SF; Hartenbach M
Eur J Nucl Med Mol Imaging; 2019 Sep; 46(10):2169-2177. PubMed ID: 31254037
[TBL] [Abstract][Full Text] [Related]
8. Oligodendroglioma in 68Ga-PSMA-11 and 18F-Fluciclovine PET/CT.
Pernthaler B; Nazerani Hooshmand T; Igrec J; Kvaternik H; Aigner RM
Clin Nucl Med; 2021 Apr; 46(4):e231-e232. PubMed ID: 33086280
[TBL] [Abstract][Full Text] [Related]
9. Oligometastatic Bone Disease in Castration-Sensitive Prostate Cancer Patients Treated With Stereotactic Body Radiotherapy Using 68Ga-PSMA PET/CT: TROD 09-004 Study.
Onal C; Ozyigit G; Akgun Z; Atalar B; Igdem S; Oymak E; Agaoglu F; Selek U; Guler OC; Hurmuz P; Mustafayev TZ; Akyol F
Clin Nucl Med; 2021 Jun; 46(6):465-470. PubMed ID: 33661210
[TBL] [Abstract][Full Text] [Related]
10. 68Ga-PSMA-11 PET/CT derived quantitative volumetric tumor parameters for classification and evaluation of therapeutic response of bone metastases in prostate cancer patients.
Schmidkonz C; Cordes M; Goetz TI; Prante O; Kuwert T; Ritt P; Uder M; Wullich B; Goebell P; Bäuerle T
Ann Nucl Med; 2019 Oct; 33(10):766-775. PubMed ID: 31338731
[TBL] [Abstract][Full Text] [Related]
11. Primary lymph-node staging with
Corona-Montes VE; González-Cuenca E; Fernández-Noyola G; Olarte-Casas MA; Bobadilla-Salazar D; Medrano-Urtecho HM; Asimakopoulos AD
Urol Oncol; 2021 Aug; 39(8):494.e1-494.e6. PubMed ID: 33223371
[TBL] [Abstract][Full Text] [Related]
12. The meta-analysis of the effect of 68Ga-PSMA-PET/CT diagnosis of prostatic cancer compared with bone scan.
Zhao R; Li Y; Nie L; Qin K; Zhang H; Shi H
Medicine (Baltimore); 2021 Apr; 100(15):e25417. PubMed ID: 33847640
[TBL] [Abstract][Full Text] [Related]
13. Delayed 68Ga-PSMA PET/CT Image-Guided Biopsy for Low-Grade Adenocarcinoma in Benign Prostatic Hyperplasia.
Santhosh S; Jeeva G
Clin Nucl Med; 2021 Apr; 46(4):e190-e192. PubMed ID: 33234940
[TBL] [Abstract][Full Text] [Related]
14. Impact of
Sonni I; Eiber M; Fendler WP; Alano RM; Vangala SS; Kishan AU; Nickols N; Rettig MB; Reiter RE; Czernin J; Calais J
J Nucl Med; 2020 Aug; 61(8):1153-1160. PubMed ID: 31924715
[TBL] [Abstract][Full Text] [Related]
15. A Multicenter Prospective Clinical Trial of
McCarthy M; Francis R; Tang C; Watts J; Campbell A
Int J Radiat Oncol Biol Phys; 2019 Jul; 104(4):801-808. PubMed ID: 30890448
[TBL] [Abstract][Full Text] [Related]
16. Multiphasic
Beheshti M; Manafi-Farid R; Geinitz H; Vali R; Loidl W; Mottaghy FM; Langsteger W
J Nucl Med; 2020 Oct; 61(10):1484-1490. PubMed ID: 32060214
[TBL] [Abstract][Full Text] [Related]
17. Optimal Time Point for 68Ga-PSMA-11 PET/CT Imaging in the Assessment of Suspected Metastatic Prostate Cancer in the Bladder of Postprostatectomy Patient.
Xu G; Lu Y
Clin Nucl Med; 2021 Aug; 46(8):675-676. PubMed ID: 33577202
[TBL] [Abstract][Full Text] [Related]
18. 68Ga-PSMA PET/MR-Positive Peritoneal Metastasis in the Falciform Ligament in Recurrent Prostate Cancer.
Kranzbühler B; Tran S; Zilli T; Burger IA
Clin Nucl Med; 2017 Aug; 42(8):e388-e389. PubMed ID: 28590295
[TBL] [Abstract][Full Text] [Related]
19. 68Ga-PSMA PET/CT Urachus Metastases in Recurrent Prostate Cancer With Very Low PSA Level.
Le Thiec M; Rusu D; Fleury V; Kraeber-Bodéré F; Rousseau C
Clin Nucl Med; 2019 Jan; 44(1):40-41. PubMed ID: 30540597
[TBL] [Abstract][Full Text] [Related]
20. 68Ga-PSMA-11 PET/CT for prostate cancer staging and risk stratification in Chinese patients.
Zang S; Shao G; Cui C; Li TN; Huang Y; Yao X; Fan Q; Chen Z; Du J; Jia R; Sun H; Hua Z; Tang J; Wang F
Oncotarget; 2017 Feb; 8(7):12247-12258. PubMed ID: 28103574
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
